| Literature DB >> 33292136 |
Rashmi Rana1, Shikha Joon1, Kirti Chauhan1, Vaishnavi Rathi1, Nirmal Kumar Ganguly1, Chandni Kumari2, Dharmendra Kumar Yadav2.
Abstract
Glioma predominantly targets glial cells in the brain and spinal cord. There are grade I, II, III, and IV gliomas with anaplastic astrocytoma and glioblastoma multiforme as the most severe forms of the disease. Current diagnostic methods are limited in their data acquisition and interpretation, markedly affecting treatment modalities, and patient outcomes. Circulating extracellular vesicles (EVs) or "magic bullets" contain bioactive signature molecules such as DNA, RNA, proteins, lipids, and metabolites. These secretory "smart probes" participate in myriad cellular activities, including glioma progression. EVs are released by all cell populations and may serve as novel diagnostic biomarkers and efficient nano-vehicles in the targeted delivery of encapsulated therapeutics. The present review describes the potential of EV-based biomarkers for glioma management. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Biomarker; Diagnostic; Extracellular vesicle; Glioma; Smart probes; Therapeutic
Year: 2021 PMID: 33292136 DOI: 10.2174/1568026620666201207100139
Source DB: PubMed Journal: Curr Top Med Chem ISSN: 1568-0266 Impact factor: 3.295